U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Untreated Prolymphocytic Leukemia

MedGen UID:
1792114
•Concept ID:
C5555673
•
Neoplastic Process

Definition

A finding of prolymphocytic leukemia that has not been treated. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUntreated Prolymphocytic Leukemia

Professional guidelines

PubMed

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM
Ann Oncol 2017 Jul 1;28(7):1554-1559. doi: 10.1093/annonc/mdx163. PMID: 28379307Free PMC Article
Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Robak T
Leuk Lymphoma 2004 Feb;45(2):205-19. doi: 10.1080/1042819031000139666. PMID: 15101704
Lonidamine in the treatment of chronic lymphoid leukemia.
Tura S, Cavo M, Gobbi M, Franchi P
Oncology 1984;41 Suppl 1:90-3. doi: 10.1159/000225894. PMID: 6717903

Recent clinical studies

Etiology

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM
Ann Oncol 2017 Jul 1;28(7):1554-1559. doi: 10.1093/annonc/mdx163. PMID: 28379307Free PMC Article
Rediscovering alemtuzumab: current and emerging therapeutic roles.
Gribben JG, Hallek M
Br J Haematol 2009 Mar;144(6):818-31. Epub 2009 Jan 8 doi: 10.1111/j.1365-2141.2008.07557.x. PMID: 19183194
Monoclonal antibody therapies in leukemias.
Tallman MS
Semin Hematol 2002 Oct;39(4 Suppl 3):12-9. doi: 10.1053/shem.2002.36923. PMID: 12447847
Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, Siakantaris MP
Med Oncol 2001;18(2):99-107. doi: 10.1385/mo:18:2:99. PMID: 11778765
Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Chun HG, Leyland-Jones B, Cheson BD
J Clin Oncol 1991 Jan;9(1):175-88. doi: 10.1200/JCO.1991.9.1.175. PMID: 1702143

Diagnosis

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM
Ann Oncol 2017 Jul 1;28(7):1554-1559. doi: 10.1093/annonc/mdx163. PMID: 28379307Free PMC Article
T-cell prolymphocytic leukemia with extensive cardiovascular infiltrate leading to multiple myocardial infarctions and cardiac death.
Cheng H, Feldman T, Butt Y, Chow KF, Yang XY, Bhattacharyya PK, de Vinck DC
Tex Heart Inst J 2014 Dec;41(6):626-30. Epub 2014 Dec 1 doi: 10.14503/THIJ-13-3581. PMID: 25593528Free PMC Article
Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA, Stetler-Stevenson M
Br J Haematol 2009 Apr;145(2):173-9. Epub 2009 Feb 19 doi: 10.1111/j.1365-2141.2009.07606.x. PMID: 19236377Free PMC Article
B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course.
Shvidel L, Shtalrid M, Bassous L, Klepfish A, Vorst E, Berrebi A
Leuk Lymphoma 1999 Mar;33(1-2):169-79. doi: 10.3109/10428199909093739. PMID: 10194135
Clonal chromosome changes in stimulated lymphocytes of untreated human B-cell leukemias.
Sadamori N, Han T, Minowada J, Matsui S, Sandberg AA
Cancer Res 1983 Jul;43(7):3287-91. PMID: 6850637

Therapy

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM
Ann Oncol 2017 Jul 1;28(7):1554-1559. doi: 10.1093/annonc/mdx163. PMID: 28379307Free PMC Article
Rediscovering alemtuzumab: current and emerging therapeutic roles.
Gribben JG, Hallek M
Br J Haematol 2009 Mar;144(6):818-31. Epub 2009 Jan 8 doi: 10.1111/j.1365-2141.2008.07557.x. PMID: 19183194
Alemtuzumab.
Frampton JE, Wagstaff AJ
Drugs 2003;63(12):1229-43; discussion 1245-6. doi: 10.2165/00003495-200363120-00003. PMID: 12790693
Monoclonal antibody therapies in leukemias.
Tallman MS
Semin Hematol 2002 Oct;39(4 Suppl 3):12-9. doi: 10.1053/shem.2002.36923. PMID: 12447847
Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Chun HG, Leyland-Jones B, Cheson BD
J Clin Oncol 1991 Jan;9(1):175-88. doi: 10.1200/JCO.1991.9.1.175. PMID: 1702143

Prognosis

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM
Ann Oncol 2017 Jul 1;28(7):1554-1559. doi: 10.1093/annonc/mdx163. PMID: 28379307Free PMC Article
Alemtuzumab.
Frampton JE, Wagstaff AJ
Drugs 2003;63(12):1229-43; discussion 1245-6. doi: 10.2165/00003495-200363120-00003. PMID: 12790693
B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course.
Shvidel L, Shtalrid M, Bassous L, Klepfish A, Vorst E, Berrebi A
Leuk Lymphoma 1999 Mar;33(1-2):169-79. doi: 10.3109/10428199909093739. PMID: 10194135
Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia.
Tefferi A, Bartholmai BJ, Witzig TE, Jenkins RB, Li CY, Hanson CA, Mesa RA, Phyliky RL
Cancer Genet Cytogenet 1997 Jun;95(2):173-7. doi: 10.1016/s0165-4608(96)00249-x. PMID: 9169037
Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group.
Döhner H, Ho AD, Thaler J, Stryckmans P, Sonneveld P, de Witte T, Lechner K, Lauria F, Bödewadt-Radzun S, Suciu S
J Natl Cancer Inst 1993 Apr 21;85(8):658-62. doi: 10.1093/jnci/85.8.658. PMID: 8468724

Clinical prediction guides

Alemtuzumab.
Frampton JE, Wagstaff AJ
Drugs 2003;63(12):1229-43; discussion 1245-6. doi: 10.2165/00003495-200363120-00003. PMID: 12790693
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Larson RA, Schiffer CA
J Clin Oncol 2002 Sep 15;20(18):3878-84. doi: 10.1200/JCO.2002.08.128. PMID: 12228208
B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course.
Shvidel L, Shtalrid M, Bassous L, Klepfish A, Vorst E, Berrebi A
Leuk Lymphoma 1999 Mar;33(1-2):169-79. doi: 10.3109/10428199909093739. PMID: 10194135
Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group.
Döhner H, Ho AD, Thaler J, Stryckmans P, Sonneveld P, de Witte T, Lechner K, Lauria F, Bödewadt-Radzun S, Suciu S
J Natl Cancer Inst 1993 Apr 21;85(8):658-62. doi: 10.1093/jnci/85.8.658. PMID: 8468724
Functional and phenotypic analysis of a T cell prolymphocytic leukemia.
Woods GM, Sawyer PJ, Kirov SM, Lowenthal RM, Jupe DM, Catovsky D
Leuk Res 1985;9(5):587-96. doi: 10.1016/0145-2126(85)90138-9. PMID: 3159942

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...